Project aims to raise awareness for pain research.
In an effort to educate the public about pain research and its impact on over 51.6 million Americans living with chronic pain, the US Pain Foundation has started an initiative to highlight the need for more research to improve outcomes. Titled #PainTrials, the endeavor will focus on current pain research efforts — including those being conducted through the National Institutes of Health's Helping to End Addiction Long-term® (HEAL) initiative.
According to a company press release, the organization hopes to:
"This month, we are excited to delve into the importance of pain research, and the impact research has on improved health outcomes for the millions of Americans living with the daily challenges of chronic pain," said Nicole Hemmenway, CEO, the US Pain Foundation. "We are excited to collaborate with the NIH HEAL Initiative, prominent researchers, and Humana to share the importance of pain research. A greater focus on research is vital to increase understanding and action surrounding chronic pain."
Reference: #PainTrials Initiative Seeks To Raise Awareness About The Need For Pain Research. PR Newswire. September 1, 2023. Accessed September 8, 2023. https://www.prnewswire.com/news-releases/paintrials-initiative-seeks-to-raise-awareness-about-the-need-for-pain-research-301914228.html
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.